

Special Issue

Brain Injury: New Insights into Mechanisms and Future Promising Treatments—Second Edition

Message from the Guest Editors

As the area of brain injury research continues to evolve rapidly, significant strides have been made in recent years toward understanding the complex pathophysiology of acquired brain injuries. Building upon the foundation of our previous issue, this second-edition Special Issue will focus on recent advancements and emerging strategies, including nanotechnology, tissue engineering, and other innovative approaches, to repair, regenerate, and restore central nervous system functionality. We aim to showcase cutting-edge research from preclinical and clinical studies, as well as comprehensive reviews that contextualize recent breakthroughs.

We invite submissions that investigate novel regenerative and restoration techniques, with an emphasis on bridging neuronal gaps, reconnecting severed neural pathways, and promoting neural tissue regeneration. Additionally, we encourage studies that uncover new insights into the neuropathological molecular mechanisms underlying brain injury, providing a foundation for future targeted therapies. We look forward to your contributions as we collectively advance the science of brain injury treatment and neuroregeneration.

Guest Editors

Dr. Kristina Pilipović

Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Dr. Petra Dolenc

Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Deadline for manuscript submissions

31 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/223732

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).